Thymidylate synthase disruption to limit cell proliferation in cell therapies
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.06.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Rocio Sartori-Maldonado und 9 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland. Hauptthemen laut MEDLINE: Cell Proliferation, Thymidine, Cell Differentiation, Thymidylate Synthase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HUS Group, Finnish Cultural Foundation, Helsingin Yliopisto.
Abstract (Originalsprache)
Stem and progenitor cells hold great promise for regenerative medicine and gene therapy approaches. However, transplantation of living cells entails a fundamental risk of unwanted growth, potentially exacerbated by CRISPR-Cas9 or other genetic manipulations. Here, we describe a safety system to control cell proliferation while allowing robust and efficient cell manufacture, without any added genetic elements. Inactivating TYMS, a key nucleotide metabolism enzyme, in several cell lines resulted in cells that proliferate only when supplemented with exogenous thymidine. Under supplementation, TYMS-/--pluripotent stem cells proliferate, produce teratomas, and successfully differentiate into potentially therapeutic cell types such as pancreatic β cells. Our results suggest that supplementation with exogenous thymidine affects stem cell proliferation, but not the function of stem cell-derived cells. After differentiation, postmitotic cells do not require thymidine in vitro or in vivo, as shown by the production of functional human insulin in mice up to 5 months after implantation of stem cell-derived pancreatic tissue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.
- Faculty of Biological and Environmental Sciences University of Helsinki, 00790 Helsinki, Finland; Institute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, 00790 Helsinki, Finland.
- Department of Pathology, Helsinki University Hospital, 00290 Helsinki, Finland.
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland; Children's Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland.
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland; Clinical Genetics, Helsinki University Hospital, 00290 Helsinki, Finland. Electronic address: kirmo.warti…
Förderung
- HUS Group
- Finnish Cultural Foundation
- Helsingin Yliopisto
- K Albin Johansson Foundation
- Diabetes Research Foundation
- Signe and Ane Gyllenberg Foundation
- Ida Mont Fundation
- Bo and Kerstin Hjelt Diabetes Foundation
Zitieren
APA
Sartori-Maldonado, R., Montaser, H., Soppa, I., Eurola, S., Juutila, J., Balaz, M., Puttonen, H., Otonkoski, T., Saarimäki-Vire, J., & Wartiovaara, K. (2024). Thymidylate synthase disruption to limit cell proliferation in cell therapies. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.06.014
Vancouver
Sartori-Maldonado R, Montaser H, Soppa I, Eurola S, Juutila J, Balaz M, et al. Thymidylate synthase disruption to limit cell proliferation in cell therapies. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.06.014
BibTeX
@article{SartoriMaldonado2024,
author = {Sartori-Maldonado, Rocio and Montaser, Hossam and Soppa, Inkeri and Eurola, Solja and Juutila, Juhana and Balaz, Melanie and Puttonen, Henri and Otonkoski, Timo and Saarimäki-Vire, Jonna and Wartiovaara, Kirmo},
title = {Thymidylate synthase disruption to limit cell proliferation in cell therapies},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.06.014}
}
EUVIMED